Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial

Area of Science:

• Neurology
• Pediatrics
• Clinical Trials

Background:

• Limited pharmacologic options exist for pediatric migraine prophylaxis.
• Levetiracetam, an anti-seizure medication, shows potential for migraine reduction in adults.
• This study investigates levetiracetam for preventing migraines in children.

Purpose of the Study:

• To evaluate the safety and efficacy of levetiracetam in pediatric migraine prevention.
• To assess changes in migraine frequency and intensity.
• To monitor adverse events associated with levetiracetam use.

Main Methods:

• A randomized, double-blind, placebo-controlled trial.
• Inclusion criteria: children aged 4-17 with frequent or severe migraines.
• Primary outcomes: change in monthly headache frequency and intensity; secondary outcome: adverse effects.

Main Results:

• Sixty-one participants completed the study (31 levetiracetam, 30 placebo).
• Levetiracetam significantly reduced migraine frequency and intensity compared to placebo.
• 68% of levetiracetam recipients experienced >50% episode reduction vs. 30% in placebo (p=0.007).
• Reported adverse effects included irritability, daytime sedation, and mild tics.

Conclusions:

• Levetiracetam demonstrates potential utility in preventing pediatric migraines.
• The drug may decrease the frequency and severity of migraine episodes in children.
• Levetiracetam appears to be a viable option for migraine prophylaxis in pediatric patients.